Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yoshindo
Toyama, Toyama, Japanyoshindo.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Yoshindo is a leading Japanese pharmaceutical and biotechnology company engaged in the development, manufacture, and commercialization of generic drugs, biopharmaceuticals, and biosimilars. Recent approvals and launches include Ustekinumab biosimilar for psoriasis vulgaris and psoriatic arthritis. The company partners with Biocon Biologics for ustekinumab and denosumab biosimilars in Japan, and previously with Lupin for etanercept biosimilar. Yoshindo is actively commercializing multiple products in the Japanese market, some through key strategic joint ventures.
- Therapeutic areas
- ImmunologyRheumatologyDermatologyPulmonologyNeurology
- Modalities
- Small moleculeBiosimilarMonoclonal antibodyFusion protein
- Industry
- Biotech
02
Partnerships
Biocon BiologicsLupin Limited
Beyond the preview
Go deeper on Yoshindo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yoshindo.